Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06295640 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Relative Contribution of Brain Insulin Action for Postprandial Metabolism

Study acronym: BrainInsPPM
StatusActive, Not Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study completion date: Jan 2026 to Jun 2026v6
  2. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 30 to confirmed 31
    • Primary completion date changed from estimate of Dec 2025 to Sep 5, 2025
    • Site details revised
    v5
  3. Re-verified, no change to tracked fieldsv4
  4. Start date changed from estimate of Mar 15, 2024 to Mar 18, 2024v3
  5. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date: Mar 2024 to Mar 15, 2024
    v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical trial is to clarify (i) the contribution of brain insulin action on regulation of systemic metabolism, (ii) sex-specific differences in the central regulation and (iii) the influence of the menstrual cycle in women. Therefore, participants will undergo oral glucose tolerance tests combined with a double tracer dilution technique. This approach will be compared between days with insulin delivery to the brain as nasal spray and days with placebo spray.
Trial Details
NCT Number NCT06295640
Lead Sponsor University of Ulm
Conditions
(from sponsor)		 Glucose Metabolism Disorders
Related terms Glucose Metabolism Disorders, Insulin Resistance
Enrollment 31 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov